BUFFALO, N.Y., Jan. 7, 2013 /PRNewswire/ -- Kinex Pharmaceuticals and Hanmi Pharmaceutical announced today that the first patient has been enrolled in Hanmi's Phase Ib / IIa clinical trial in Korea. Kinex's dual Src/pretubulin Inhibitor, KX01, is being combined with intravenous (IV) paclitaxel to treat solid tumor patients in Phase Ib and then gastric and breast cancer patients in Phase IIa.
KX01 (KX2-391) is an once daily, orally administered potent small molecule Src kinase/pretubulin dual mechanism inhibitor discovered by Kinex Pharmaceuticals using its proprietary technology platforms Mimetica™and Opal™. KX01 differentiates itself as a non-ATP competitive Src signaling inhibitor and, therefore, offers excellent efficacy as well as safety profile. KX01 has been shown to be very effective against a broad range of cancers in both in vitro experiments and in animal cancer models. Importantly, the compound has synergistic activities with most taxanes, including paclitaxel which is combined with KX01 in the current Phase Ia / IIb trial. A completed Phase I study, in patients with end-stage cancer and twice daily dosing, showed a desirable safety profile and clinical stable diseases in approximately 25% of the patients. An ongoing KX01 AML mono-therapy Phase I trial has shown that once daily dosing allows much higher KX01 blood levels to be achieved while still maintaining and excellent safety profile. The composition of matter, use and synthesis/formulation of KX01 is covered by issued and pending patents globally.
David Hangauer, CSO of Kinex, commented, "We are delighted that the Hanmi team continues to be excellent partners for the development of KX01. We are very excited that they have initiated the KX01 / paclitaxel trial. KX01 has shown strong synergy in vitro and in vivo with paclitaxel and it will be an important advancement in cancer therapy if such synergy is also present in actual clinical setting."
"Hanmi filed their Korean IND in the 3Q of 2012, it was approved in the 4Q of 2012, and they have now enrolled their first patient. Their commitment to the KX01 program is extraordinary," said Dr. Rudolf Kwan, CMO of Kinex. "I have visited the Korean clinical sites and am extremely pleased with the very high clinical research standard set by our partner, Hanmi. The KX01 program is important in its own right, but it also allows us to further refine our strategy of combining KX01 with Oraxol, an oral paclitaxel product discovered by Hanmi that is currently being developed through a joint development program between Kinex and Hanmi."
Dr. Jeewoong Son, Senior VP and Head of Innovation at Hanmi added, "The Hanmi and Kinex teams worked together very diligently to submit our Korean IND in a timely manner. We are pleased to see Kinex's strong commitment to aggressively move forward with KX01 and the Orascovery program. We hope that our joint effort will lead to an oral treatment that provides an important new option for many cancer patients."
About Kinex Pharmaceuticals
Kinex Pharmaceuticals, headquartered in Buffalo, New York, USA, is using its proprietary technologies Mimetica and Opal to discover and develop novel drugs for oncology and immune-modulatory diseases. More information of Kinex Pharmaceuticals can be found at www.kinexpharma.com
About Hanmi Pharmaceutical, Co., Ltd
Established in 1973 in Korea, Hanmi Pharmaceuticals now is one of the top 5 pharmaceutical companies in terms of revenue, and the most R&D focused company with the highest R&D investment for several years. Hanmi has been successful for a few decades with high flexibility, continuously changing its market/development strategy from first generics to IMD & FDC (Incrementally Modified Drug and Fixed Dose Combination) to new drug development including innovative small molecules and biologics. During the period of significant changes, Hanmi made multiple strategic collaboration relationships with multinational companies and biotech companies.
For further information about Hanmi Pharmaceuticals, please refer to www.hanmipharm.com
Vice President, Business Development and Investor Relations
701 Ellicott Street
Buffalo, NY 14203
SOURCE Kinex Pharmaceuticals